Analysts See $-0.04 EPS for Alimera Sciences, Inc. (ALIM)

April 23, 2018 - By Maria Brooks

Alimera Sciences, Inc. (NASDAQ:ALIM) LogoInvestors sentiment decreased to 1 in Q4 2017. Its down 0.64, from 1.64 in 2017Q3. It dived, as 4 investors sold Alimera Sciences, Inc. shares while 8 reduced holdings. 3 funds opened positions while 9 raised stakes. 28.68 million shares or 0.99% more from 28.40 million shares in 2017Q3 were reported.
8,099 were accumulated by Jpmorgan Chase &. Barclays Public Limited Co holds 93 shares or 0% of its portfolio. Blackrock invested in 210,886 shares. Susquehanna Int Group Ltd Liability Partnership holds 26,098 shares. Bridgeway Cap owns 0.01% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 589,825 shares. Moreover, Cambridge Research Advsrs has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 23,800 shares. Morgan Stanley reported 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Bnp Paribas Arbitrage has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Two Sigma Securities reported 0% stake. Venbio Select Advisor Ltd reported 6.24 million shares. Renaissance Lc invested in 0% or 416,400 shares. Citadel Advsrs Ltd Company has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 54,299 shares. Knott David M reported 0.11% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Valley Natl Advisers holds 400 shares or 0% of its portfolio. Palo Alto Ltd Llc accumulated 3.01 million shares or 0.17% of the stock.

Since January 16, 2018, it had 1 insider buy, and 10 sales for $290,803 activity. Another trade for 25,500 shares valued at $31,475 was sold by Ashman Philip. $14,181 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) was sold by Green Kenneth. 25,500 shares valued at $30,552 were sold by Holland David on Thursday, January 18. Myers C. Daniel also sold $65,294 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) on Tuesday, January 16. ARMISTICE CAPITAL – LLC bought $22,800 worth of stock or 20,000 shares.

Analysts expect Alimera Sciences, Inc. (NASDAQ:ALIM) to report $-0.04 EPS on May, 14.They anticipate $0.06 EPS change or 60.00 % from last quarter’s $-0.1 EPS. After having $-0.10 EPS previously, Alimera Sciences, Inc.’s analysts see -60.00 % EPS growth. It closed at $1.12 lastly. It is down 28.28% since April 23, 2017 and is downtrending. It has underperformed by 39.83% the S&P500.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $78.38 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.